Lilly Licenses Merck KGaA Insomnia Agent EMD 281014
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I 5-HT2a antagonist also has potential for use in other central nervous system disorders, Lilly says. Possible benefits in sleep category include less next-day side effects and use in broad patient population.